BJMO - volume 19, issue 3, may 2025
C. Gennigens MD, PhD, A. Lebeau PhD
Although progress has been made through screening and vaccination against human papillomavirus (HPV), locally advanced (LACC) and metastatic cervical cancer continue to present significant therapeutic challenges. Indeed, the treatment strategies have remained largely unchanged for almost twenty years. In the LACC setting, recent research has focused on improving standard treatment (chemoradiation followed by brachytherapy), including neo-adjuvant chemotherapy (INTERLACE trial) or addition of an immune checkpoint inhibitor (ICI) (ENGOT-Cx11 study). In metastatic disease, immunotherapy is also making strides, encompassing ICIs in the first-line treatment; but also, tumour-infiltrating lymphocytes (TILs) transfer and therapeutic vaccination are still in clinical trials. The antibody-drug conjugate (ADC) tisotumab vedotin has demonstrated efficacy in second- or third-line therapy, while other ADCs targeting HER2 and TROP2 are under investigation. These innovative treatments offer hope for improving survival outcomes in patients with cervical cancer.
(BELG J MED ONCOL 2025;19(3):88–95)
Read moreBJMO - volume 18, issue 5, september 2024
C. Gennigens MD, PhD, A. Lebeau PhD
In the field of gynaecologic oncology, numerous studies were presented at the 2024 ASCO Annual Meeting. Several therapeutic de-escalation strategies were discussed, including the lack of benefits from lymphadenectomy in advanced ovarian cancer and from adjuvant chemotherapy in early high-risk cervical cancer. Neoadjuvant combined with adjuvant PARP inhibitors for patients with resectable recurrent ovarian tumours is a promising approach to avoid chemotherapy and enhance quality of life. Among the new treatments, mirvetuximab soravtansine for platinum-resistant ovarian cancers and selinexor for advanced or recurrent TP53 wild-type endometrial tumours are particularly promising. Additionally, several trials have explored the impact of obesity and its management in gynaecological cancers.
(Belg J Med Oncol 2024;18(5):211–5)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
